Based: New York, NY
Stock symbol: STML
Range: $10 to $12
IPO price: $10
Close Oct. 17: $37.99
Change: Up 279%
Raised: $38 million

The scoop: Stemline is one of those biotechs that has benefited from the big focus on biotech IPOs in general and cancer stem cells in particular. The first biotech IPO of the year priced at the bottom of its range, not bad at the time, but has since zoomed up on some fervid expectations. Some analysts have attributed significant weight to early results from tiny studies which reflect some impressive--but preliminary--results for its IL-3 strategy. Another biotech, Verastem ($VSTM), recently pieced together a successful IPO with its cancer stem cell study. Stemline is planning to put its lead drug into a pivotal study involving patients with relapsed or refractory acute myeloid leukemia, while another treatment--701--will be pushed into a pediatric study for brainstem glioma and a separate trial for adult glioblastoma, or brain cancer. The stock price on Stemline has been very volatile, not unusual after such a huge runup.

For more:
First biotech IPO of '13 jumps in encouraging debut
Stemline delays IPO to fund cancer drugs
Stemline bets $50M IPO on a pair of cancer stem cell treatments
Tiny Stemline's brain cancer vax grabs a little of ASCO's limelight


Suggested Articles

Yale scientists have combined the gene-editing system CRISPR with gene therapy to help the immune system find tough-to-spot tumor cells.

The planned deal hit a wall when a special committee set up by Eidos turned down BridgeBio’s third and final offer.

Shares in ReNeuron fell more than one-third after the release of top-line data at the start of the month but the biotech argued the data are positive.